PremaAbrahamMD

Ophthalmology • Rapid City, SD

Retinal Disease

Medical Director The Retina Center Black Hills Regional Eye Institute

Join to view full profile

Dr. Abraham is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Abraham's full profile

Already have an account?

Office
2800 3rd St
Rapid City, SD 57701
Phone+1 605-341-2000

Fax+1 605-719-3211
Is this information wrong?

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalFellowship, Surgical Retina and Vitreous, 1993 - 1995
University of Utah HealthResidency, Ophthalmology, 1990 - 1993
University of Arkansas For Medical Sciences College of MedicineClass of 1989

Certifications & Licensure

SD State Medical License Active through 2025
WY State Medical License 2021 - 2024
UT State Medical License 1990 - 1996
PA State Medical License 1993 - 1996
AR State Medical License 1989 - 1991
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Medflow EHR, Medflow, Inc., 2012-2013

Clinical Trials

Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study Start of enrollment: 2010 Feb 01
Completed
Phase 2
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) Start of enrollment: 2012 Feb 01
Terminated
Phase 2
Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment Start of enrollment: 2012 Nov 01
Completed
Phase 4
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Start of enrollment: 2014 Sep 01
Completed
Phase 3
Ocriplasmin Research to Better Inform Treatment (ORBIT) Start of enrollment: 2014 May 01
Completed
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration Start of enrollment: 2014 Sep 17
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

10 citations
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Charles C Wykoff, David M Brown, Kimberly Reed, Alyson J Berliner, Adam T Gerstenblith, Aurora Breazna, Prema Abraham, Jordana G Fein, Karen W Chu, W Lloyd Clark, Serg...> ;JAMA Ophthalmology. 2023 Sep 1
9 citations
Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
Clement K Chan, Maziar Lalezary, Prema Abraham, Michael Elman, Wesley Thomas Beaulieu, Steven G Lin, Rahul N Khurana, Alok S Bansal, Mark R Wieland, James D Palmer, Lo...> ;Ophthalmology. Retina. 2022 Jun 1
1 citations
Post-hoc analysis of single nucleotide polymorphism profile for eyes with vascularized pigment epithelial detachment due to ARMD.
Daniel Lee, Clement K. Chan, Prema Abraham, David Sarraf> ;European Journal of Ophthalmology. 2021 May 1
Single nucleotide polymorphism profiles associated with three common phenotypes of advanced age-related macular degeneration.
Caleb Ng, Clement K. Chan, Prema Abraham, Andre D Hafner> ;Acta Ophthalmologica. 2021 Feb 1
3 citations
Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case s...
Clement K. Chan, David Sarraf, Prema Abraham, Maziar Lalezary, Steven G. Lin, Xuejing Chen, Muneeswar Gupta Nittala, Srinivas R. Sadda> ;American Journal of Ophthalmology Case Reports. 2020 Dec 1
269 citations
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
David Liao, Federico Grossi, Delphine El Mehdi, Monica Gerber, David M. Brown, Jeffrey S. Heier, Charles C. Wykoff, Lawrence J. Singerman, Prema Abraham, Felix Grassma...> ;Ophthalmology. 2020 Feb 1
2 citations
Treatment outcomes of conventional or high-dose ranibizumab for vascularized pigment epithelial detachment based on lesion subtypes.
Clement K. Chan, David Sarraf, Prema Abraham> ;European Journal of Ophthalmology. 2018 Mar 25
5 citations
TYPE 1 VERSUS TYPE 3 NEOVASCULARIZATION IN PIGMENT EPITHELIAL DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTO...
Xuejing Chen, Mayss Al-Sheikh, Clement K Chan, Amir H Hariri, Prema Abraham, Maziar Lalezary, Steven G Lin, SriniVas Sadda, David Sarraf> ;Retina. 2016 Dec 1
31 citations
Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degenera...
Clement K. Chan, P Abraham, David Sarraf, A S D Nuthi, Steven G. Lin, Colin A. McCannel> ;Eye. 2015 Jan 1
Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab.
Channa R Sophie R Khwaja AA Do DV Hafiz G Nguyen QD Campochiaro PA> ;Eye (Lond). 2014 Mar
55 citations
PROSPECTIVE EVALUATION OF THE INCIDENCE AND RISK FACTORS FOR THE DEVELOPMENT OF RPE TEARS AFTER HIGH- AND LOW-DOSE RANIBIZUMAB THERAPY
David Sarraf, Clement K. Chan, Ehsan Rahimy, Prema Abraham> ;Retina. 2013 Sep 1
Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment.
Do DV Nguyen QD Khwaja AA Channa R Sepah YJ Sophie R Hafiz G Campochiaro PA> ;JAMA Ophthalmol. 2013 Feb
9 citations
High-dose ranibizumab therapy for vascularized pigment epithelial detachment
Clement K. Chan, P Abraham, David Sarraf> ;Eye. 2012 Jun 1
70 citations
Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration.
David M. Brown, Jeffrey S. Heier, Thomas A. Ciulla, Matthew S. Benz, Prema Abraham, George D. Yancopoulos, Neil Stahl, Avner Ingerman, Robert Vitti, Alyson J. Berliner...> ;Ophthalmology. 2011 Jun 1
41 citations
Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial
Jeffrey S. Heier, David M. Brown, Thomas A. Ciulla, Prema Abraham, Joy M. Bankert, Sandy Chong, Paul E. Daniel, Ivana K. Kim> ;Ophthalmology. 2011 Jan 1
394 citations
Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
Quan Dong Nguyen, Syed Mahmood Shah, Afsheen Khwaja, Roomasa Channa, Elham Hatef, Diana V. Do, David S. Boyer, Jeffery S. Heier, Prema Abraham, Allen B. Thach, Eugene ...> ;Ophthalmology. 2010 Nov 1
636 citations
Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2
Prema Abraham, Huibin Yue, Laura Wilson> ;American Journal of Ophthalmology. 2010 Sep 1
308 citations
Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab...
Clement K. Chan, Prema Abraham, Carsten H. Meyer, Gregg T. Kokame, Peter K. Kaiser, Michael E. Rauser, Jeffrey G. Gross, Asha S. D. Nuthi, Steven G. Lin, Noha Daher> ;Retina. 2010 Feb 1
254 citations
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
Quan Dong Nguyen, Syed Mahmood Shah, Jeffery S. Heier, Diana V. Do, Jennifer I. Lim, David S. Boyer, Prema Abraham, Peter A. Campochiaro> ;Ophthalmology. 2009 Nov 1
24 citations
Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence® [triamcinolone acetonide injectable suspension] 40 MG/ML) for visualizati...
David Dyer, David Callanan, Thomas Bochow, Prema Abraham, H Michael Lambert, S Young Lee, Todd E. Schneiderman, Susan L. Potts, Thomas M. Walker> ;Retina. 2009 Jan 1
665 citations
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
Carl D. Regillo, David M. Brown, Prema Abraham, Huibin Yue, Tsontcho Ianchulev, Susan Schneider, Naveed Shams> ;American Journal of Ophthalmology. 2008 Feb 1
56 citations
Intravitreal bevacizumab (avastin) in central retinal vein occlusion.
Jason Hsu, Richard S. Kaiser, Arunan Sivalingam, Prema Abraham, Mitchell S. Fineman, Michael A. Samuel, James F. Vander, Carl D. Regillo, Allen C. Ho> ;Retina. 2007 Oct 1
352 citations
Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
Clement K. Chan, Carsten H. Meyer, Jeffrey G. Gross, Prema Abraham, Asha S. D. Nuthi, Gregg T. Kokame, Steven G. Lin, Michael E. Rauser, Peter K. Kaiser> ;Retina. 2007 Jun 1
Join now to see all

Press Mentions

Christopher A. Durham, MD, Vascular SurgeonJuly 20th, 2021

Hospital Affiliations

Monument Health Rapid City HospitalRapid City, South Dakota
Monument Health Custer HospitalCuster, South Dakota
Black Hills HCSFort Meade, South Dakota
Sheridan VA Medical CenterSheridan, Wyoming
Fargo VA Medical CenterFargo, North Dakota
Royal C. Johnson Veterans' Memorial HospitalSioux Falls, South Dakota